Search

Backgroung: The iatrogenic effects of psychotropic drugs in patients suffering from psychiatric diseases are frequent, negatively impacting compliance, hence the need to study them to minimize the risk of occurrence. Aim: To study psychotropic drugs side effects prescribed and compliance with treatment. Methods: This is a cross-sectional descriptive study using an anonymous questionnaire, covering adult patients, treated on an outpatient basis at the Ibn Nafis psychiatric hospital in Marrakech, Morocco. It took place between May and June 2023. The compliance degree was determined according to the Morisky questionnaire. The side effects imputability study followed the French method. Results: Two hundred patients were consulted with an average age of 43.92 years, and a F/M sex ratio of 1.38. Approximately 45 % of treatments administered were antipsychotics. The respondents were followed mainly for psychotic disorders (42.5%), followed by anxiety-depressive disorders (42%). With an average compliance score of 8, 43% of patients were considered good adherents to treatment. A total of 1801 side effects were identified in 200 patients, with mainly neurological effects, followed by neurovegetative, endocrine and psychological and cognitive effects. Conclusion: This study clearly shows the reality and psychotropic treatments side effects importance in these patients followed on an outpatient basis. It would be interesting to develop a therapeutic education activity with this category of patients in order to improve the detection and side effects management. [ABSTRACT FROM AUTHOR]

Copyright of Actualités Pharmaceutiques is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The transfusion of blood and blood components is a life-saving medical procedure, however, it is linked with adverse reactions to transfusions. Information about different types of adverse transfusion reactions (ATRs) will assist in their early identification and subsequent management, as well as in devising strategies to minimize the occurrence of adverse reactions related to blood component transfusion. The current study was therefore executed to analyze the pattern of ATRs in patients with burn injuries at a national burn center. This was a cross-sectional, prospective study involving an analysis of immediate ATRs from January 2020 to June 2021 (18 months). ATRs observed during the study period were documented and analyzed. During the study period, 2,220 units of blood and blood components were transfused to 1,075 burn patients (2.06 transfusions per patient). A total of 27 ATRs were recorded (1.21%). Allergic reactions were the commonest (55.55%) followed by febrile non-haemolytic transfusion reaction (37.03%). The mean volume of blood unit transfused, when the reactions were noted, was approximately 75 ml (range: 15-230 ml). The mean time at which transfusion reactions were noted was 17 min (range: 5-220 minutes). The ATRs were more common in patients with multiple transfusions compared to those receiving a single transfusion. The common adverse reactions were allergic and febrile non-haemolytic transfusion reactions. It is vital to report all transfusion reactions to the attached blood center and hospital transfusion committee (HTC) on standardized reporting forms. Continuous medical education through seminars and sensitization workshops will support consolidating haemovigilance systems. [ABSTRACT FROM AUTHOR]

Psychiatric disorders are common co-existing conditions in children with epilepsy and can precede or follow epilepsy onset. Therefore, when selecting anti-seizure medications (ASMs) for children with epilepsy, in addition to seizure control, careful consideration of behavioral and psychotropic effects (BPEs) is critical, as they can have a negative impact on ASM adherence and quality of life. The goal in supporting children with epilepsy is an individualized approach to maximize seizure control and minimize negative BPEs. A previous history of a psychiatric disorder is the most significant risk factor for negative BPEs. Therefore, systematic screening for psychiatric symptoms can guide ASM selection and prompt intervention as needed. Besides familiarity with different ASM profiles, awareness of risk factors for negative BPEs including rapid dose titrations and weaning schedules, polypharmacy, high ASM doses, and drug interactions are important. In children with co-existing psychiatric disorders, ASMs with mood stabilizing, behavior regulating or anxiolytic properties may be preferred choices. Overall, a comprehensive and coordinated approach, with family psychoeducation and a mutual understanding of clinical aspects between the disciplines of neurology and psychiatry will enable better outcomes in children with epilepsy. Further pediatric "real-world" studies will expand knowledge of BPEs and potential risk factors. For some children, timely epilepsy surgery or precision therapies targeting a pathological defect may reduce the ASM burden in a child's life and subsequent BPEs. The ability to predict an individual child's susceptibility to negative BPEs with valid biomarkers may become available in the near future with advances in pharmacogenomics and technology. [ABSTRACT FROM AUTHOR]

Copyright of Actualités Pharmaceutiques is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Les médicaments possédant des propriétés anticholinergiques sont très souvent prescrits et délivrés. Qu'elles soient recherchées ou méconnues, ces propriétés exposent les patients à un certain nombre d'effets indésirables centraux et périphériques désignés sous le terme de syndrome anticholinergique. Les événements indésirables iatrogéniques de ce type sont encore très fréquemment rencontrés, en particulier chez les sujets âgés. Drugs with anticholinergic properties are frequently prescribed and dispensed. Whether sought after or not, these properties expose patients to a number of central and peripheral adverse effects referred to as anticholinergic syndrome. Iatrogenic adverse events of this type are still very frequently encountered, particularly in elderly subjects. [ABSTRACT FROM AUTHOR]

Introduction: Tardive seizure refers to a spontaneous seizure, which occurs after electroconvulsive therapy (ECT). It is a rare and poorly understood phenomenon that can lead to other serious consequences such as status epilepticus. Risk factors may be associated, and its management is by no means consensual. However, tardive seizure remains little explored in the absence of feedback and data sharing. The purpose of this study was to report the prevalence of late-onset seizures following ECT during the acute phase of treatment at the stimulation unit of Razi Hospital during its seven years of activity and to identify variables associated with this adverse event., Methods: This is a descriptive and retrospective study that was carried out at the ECT unit of Razi Hospital, Tunisia, based on the medical records of patients treated with ECT between December 2015 and September 2023. Every recorded ECT session during the initial course of treatment with available EEG tracings was included in the study. Maintenance ECT sessions, undocumented sessions, those without clinical observations, and/or those without EEG tracings were all excluded. A tardive seizure was retained according to criteria that included both recorded motor manifestations such as "motor jerks" or "generalized tonic-clonic seizures" which began spontaneously after ECT and the resumption of a state of consciousness concurrent with an equivocal EEG tracing., Results: A total of 162 patients received at least one course of ECT during the research period. Ultimately, we included 1931 well documented sessions that were completed for 157 patients in all. Of the 157 patients, seven had experienced at least one late seizure after receiving ECT, accounting for 4.45% of patients. Among the 1931 sessions, 11 late seizures were noted. The prevalence of tardive seizures in our series was 0.57%. Several factors have been associated to the onset of a tardive seizure, including being a male, the presence of a neurological lesion, treatment that lowers the epileptogenic threshold, anesthesia with etomidate, stimulation charge near seizure threshold or maximum electrical load, prolonged induced seizure, and poor post-ictal suppression on the induced seizure tracing., Conclusion: Despite the dearth of information, tardive seizure following ECT is considered to be a rare event. Risk factor management would be the first action to be taken to prevent such an event., Competing Interests: Disclosure of interest The authors declare that they have no competing interest., (Copyright © 2024 L'Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.)

Introduction: Bariatric surgery is the only treatment for severe obesity (BMI>35kg/m 2 ) currently recognized as effective both in achieving tangible and lasting weight loss, and in improving obesity-related comorbidities such as type 2 diabetes, hypertension, and cardiovascular complications. Bariatric surgery, like any other surgery of the digestive tract, can have an impact on nutrient absorption, as well as on drug absorption. The literature on drug management in bariatric surgery patients concerned mainly of case reports and retrospective studies involving a small number of patients. No official guidelines are available., Methods: We conducted a literature search on the consequences of bariatric surgery in terms of drug bioavailability and/or effect. The Medline® (PubMed) database was searched using the following keywords: "bariatric surgery", "bioavailability", "gastric bypass", and "obesity". We completed this review with an analysis of reports of adverse drug reactions (ADRs) in post-bariatric surgery patients for obesity registered in the National pharmacovigilance database (PVDB). We selected all cases with the mention of "bariatric surgery and/or gastrectomy" as "medical history". After reading the cases, we excluded those in which the patient had undergone surgery for an indication other than obesity, where the route of administration was other than oral, and cases in which ADRs resulted from voluntary overdose, attempted suicide, allergy, switch to Levothyrox® new formulation, meningioma under progestative drugs, inefficacy related to generic substitution and medication error., Results: The literature search identified mainly "case report" about the impact of bariatric surgery on so-called "narrow therapeutic window" drugs. We identified 66 informative cases out of a total of 565 cases selected (11%) in the PVDB. Nevertheless, the information does not allow a clear relationship between the occurrence of the ADR and the influence of bariatric surgery., Conclusion: There is a lack of official information and/or recommendations on medication use in subjects who have undergone bariatric surgery. Apart from under-reporting, ADRs reports remain largely uninformative. Health professional and patients would be awareness for improving, quantitatively and qualitatively the reporting of ADRs in this population., (Copyright © 2024 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)

High-risk drugs, which are potentially a source of serious adverse reactions, are a major concern in healthcare establishments, particularly for geriatric patients, who often have multiple medications and co-morbid conditions. With a view to continuously improving the quality and safety of care, we have embarked on a proactive approach aimed at identifying, securing and improving the management of medicines at risk in geriatric wards., (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)

Copyright of Actualités Pharmaceutiques is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

L'annonce du diagnostic de cancer constitue un traumatisme pour le patient. Celle d'une rechute ou d'une récidive l'est tout autant. Le sentiment d'être mortel entraîne une multitude de réactions souvent incompréhensibles pour une personne en bonne santé. Afin de mener à bien un entretien "chimiothérapie orale", il est important d'avoir des notions de psycho-oncologie. The announcement of a cancer diagnosis is traumatic for the patient. The news of a relapse or recurrence is just as traumatic. The feeling of being dead leads to a multitude of reactions that are often incomprehensible to a healthy person. In order to carry out an "oral chemotherapy" interview, it is important to have some knowledge of psycho-oncology. [ABSTRACT FROM AUTHOR]

La mise sur le marché des chimiothérapies orales a considérablement amélioré la prise en charge des patients atteints d'un cancer. En dépit de leurs avantages, ces médicaments restent associés à de nombreux effets indésirables qu'il convient d'anticiper et de prévenir. The introduction of oral chemotherapies has significantly improved the management of cancer patients. Despite their benefits, these drugs are still associated with many adverse events that need to be anticipated and prevented. [ABSTRACT FROM AUTHOR]

Le préparateur en pharmacie d'officine est un acteur de santé de premier recours pour la personne âgée face à son traitement. Il a donc un rôle important dans la prévention de l'iatrogénie médicamenteuse. Comprendre les principaux facteurs de risque de survenue des effets indésirables chez le sujet âgé permet d'améliorer le bon usage des médicaments dans cette population. The pharmacy technician is the first line of health care for the older adults in relation to their treatment. They therefore have an important role to play in the prevention of drug-related problems. Understanding the main risk factors for the occurrence of adverse drug reactions in the older adults helps to improve the good use of medicines in this population. [ABSTRACT FROM AUTHOR]

Copyright of Actualités Pharmaceutiques is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

La prise d'un traitement immunosuppresseur à vie est obligatoire après une transplantation. L'immunosuppression permet de prévenir le rejet du greffon par l'organisme receveur en limitant la réponse immunitaire acquise. Pourvoyeurs de nombreux effets indésirables, les immunosuppresseurs ont une marge thérapeutique étroite et doivent faire l'objet d'un suivi particulier. Life-long immunosuppression is mandatory after organ transplantation. It prevents graft rejection by limiting the acquired immune response. Immunosuppressive drugs induce many adverse effects and display a narrow therapeutic window justifying their close monitoring. [ABSTRACT FROM AUTHOR]

L'intoxication au lithium peut entraîner des complications neurologiques graves comme une altération de la conscience et un tableau d'encéphalopathie, avec un risque de décès ou de séquelles au long cours. Avec une présentation parfois atypique, voire même sans hyperlithiémie plasmatique initiale, le retard au repérage de ces complications peut être important. De plus, aucune recommandation spécifique de ces complications n'est disponible dans la littérature. L'objectif de cet article est de proposer une mise au point concernant la prise en charge diagnostique et thérapeutique des complications neurologiques, telles que l'encéphalopathie, imputables au lithium. Lithium intoxication may induce neurological complications, initially characterised by a conscience alteration and an encephalopathy clinical picture with a risk of death or sever long-term consequences. With an occurrence sometimes atypical and possibly without initial hyperlitemia, the diagnosis delay of these complications might be important. Moreover, no specific guidelines focused on these complications are available. The aim of this article is to propose an update on diagnosis and treatment of neurological complications attributable to lithium, as encephalopathy. [ABSTRACT FROM AUTHOR]

Une banalisation de l'emploi des anticancéreux par voie orale est souvent observée. Le pharmacien doit informer les patients de la toxicité cutanéo-muqueuse et phanérienne de ces médicaments, leur donner des conseils applicables au quotidien et leur permettre d'identifier facilement les premiers symptômes de ces effets indésirables. Alopécie, mucites, atteintes unguéales, toxicités cutanées, photosensibilité, éruptions acnéiformes ou rashs cutanés doivent être prévenus et maîtrisés au maximum. The use of oral cancer drugs is often trivialised. The pharmacist must ensure patients are aware of the toxic effects these drugs can have on the mucous membranes, skin and skin appendages, give them advice applicable to their daily lives and help them identify the early symptoms of these adverse effects. Hair loss, mucositis, nail changes, skin toxicity, photosensitivity, acneiform eruptions or skin rashes must be prevented and controlled as best as possible. [ABSTRACT FROM AUTHOR]

Parmi les nombreux sujets abordés lors du congrès de l' European Society for Medical Oncology 2019, certains permettent à l'équipe officinale d'actualiser ses connaissances. Elle peut ainsi optimiser le conseil pharmaceutique face aux multiples questions que le patient cancéreux est susceptible de poser. Among the many different topics discussed at the 2019 European Society for Medical Oncology conference, some enable pharmacy teams to refresh their knowledge. They are thereby better armed to deal with the many questions which patients with cancer are likely to have. [ABSTRACT FROM AUTHOR]

Many transfused patients present severe, sometimes critical, clinical conditions. The occurrence of adverse transfusion reactions may cause the clinical condition to deteriorate. A study was conducted aimed at establishing whether the presence of neurological signs during an adverse transfusion reaction increases its severity. From 1 January 2010 to 30 June 2019, adverse reactions with neurological signs were extracted from the French haemovigilance database system. Two signs observed at the time of the reaction were analysed: unconsciousness and convulsions. Stroke was excluded. The type of reaction, its severity, the blood product involved and its imputability were all studied. During the study period, 10,670 reactions were reported, including 20 (0.19%) imputed to the transfusion with unconsciousness and/or convulsions. Unconsciousness without convulsions was frequently observed (14 reports, 70.0%). Convulsions were reported in 5 cases (25.0%), with 1 case being associated with unconsciousness. Unconsciousness and/or convulsions were present in 9 allergic reactions (45.0%) and 4 transfusion-associated circulatory overloads (20.0%). Nine reactions were severe (45.0%), 7 were life-threatening (35.0%) and 1 case resulted in the recipient's death (5.0%). A red blood cell and a platelet concentrate transfusion were involved in 8 reactions (40.0%) each, although the imputability of the blood product was certain in only 2 of the reactions. Unconsciousness and/or convulsions were rarely observed in adverse reactions reported in transfused patients. Nevertheless, the presence of these signs highlights the severity of the adverse reactions (17 reactions, 85.0%). [ABSTRACT FROM AUTHOR]

Introduction: This case report describes the long-term success of a subcutaneous ureteral bypass device in a dog for treatment of a ureteral obstruction. The suspected xanthine urolithiasis was secondary to treatment with allopurinol for leishmaniasis. The dog presented initially with lethargy, anuria and abdominal pain. Mild azotemia was found on biochemical analysis and abdominal ultrasound revealed bilateral ureteral obstruction. A subcutaneous ureteral bypass was subsequently placed using a standard surgical technique. The dog recovered uneventfully and the azotemia resolved within days. Follow-up examinations were performed every trimester for over three years and no complications like obstruction of the bypass tubes, urinary tract infection or azotemia were recognized during this follow-up period. Allopurinol was replaced with domperidone as long-term treatment against Leishmaniasis which resulted in a mild increase of the leishmania serum antibody titer. The subcutaneous ureteral bypass placement was successful and safe in this dog and is a valuable alternative in cases of ureteral obstruction also in dogs.

Copyright of Phytothérapie is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

La iatrogénie médicamenteuse des troubles prostatiques est peu étudiée. Quelques événements sont rapportés dans la littérature scientifique avec un niveau de preuve variable lorsqu'ils sont évoqués. Une synthèse des données disponibles, cliniques ou expérimentales, a permis de rassembler des informations sur les médicaments ayant des effets indésirables sur la prostate, avérés ou potentiels, et de les classer d'après le niveau de preuve. Drug iatrogenesis of prostate disorders is poorly studied. Some events are reported in the scientific literature with a varying level of evidence when they are mentioned. A synthesis of available clinical or experimental data was used to gather information on medications with known or potential side effects on the prostate gland and to classify them according to the level of evidence. [ABSTRACT FROM AUTHOR]

Résumé: Les toxidermies sont des complications cutanéomuqueuses secondaires à l'administration par voie systémique de médicaments. Cet article fait la synthèse de ces publications des dernières années, dans la littérature et dans le cadre de congrès internationaux. Elle est orientée vers les toxidermies à allopurinol. [ABSTRACT FROM AUTHOR]

La réintroduction d'un médicament après la survenue d'un problème iatrogénique peut permettre de le mettre en cause. Deux cas cliniques, l'un concernant les corticoïdes et l'autre la codéine, illustrent cette situation. The reintroduction of a drug after the occurrence of a iatrogenic issue may cause it's use to be questioned. Two clinical cases, one involving corticosteroids and the other codeine, illustrate this situation. [ABSTRACT FROM AUTHOR]

La prise en charge médicamenteuse de l'hypertension artérielle (HTA) entraine des effets indésirables qui peuvent être gênants et ainsi influencer l'observance du patient. Nous avons étudié ces effets indésirables dans le service de cardiologie du Centre hospitalier universitaire Yalgado Ouédraogo afin de déterminer leurs fréquences et leurs caractéristiques. Il s'agissait d'une étude transversale de juillet à septembre 2015 chez les patients suivis en ambulatoire pour HTA. Les données ont été obtenues à partir de l'interrogatoire, des carnets de suivi des patients et des fiches de consultations. Au total 278 patients ont été inclus. La population d'étude incluait 69,1% de femmes. L'âge moyen était de 52,2 ans avec des extrêmes de 23 et 86 ans. Quatre vingt et sept virgule huit pourcent (87,8%) vivaient en milieu urbain. Le tabagisme, la dyslipidémie et les antécédents familiaux d'HTA représentaient respectivement 9%, 35,6% et 57,2%. Au plan thérapeutique, 43,2% étaient sous monothérapie, 35,6% sous bithérapie à l'initiation du traitement. Les inhibiteurs calciques (59,7%) étaient la classe thérapeutique la plus utilisée. La prévalence globale des effets indésirables était de 60,1%. Les inhibiteurs calciques étaient impliqués dans 53,6% suivis des diurétiques (48,6%) dans la survenue de l'effet indésirable. La prévalence spécifique par molécule était 28,1% pour l'amlodipine et 24,5% pour l'hydrochlorothiazide. La diurèse excessive (13,7%), la toux (12,9%) et les vertiges (11,5%) étaient les effets indésirables les plus fréquemment évoqués par les patients. Le système nerveux central et périphérique et le système ostéo-musculaire étaient les systèmes les plus atteints. Les effets indésirables sont un déterminant majeur de l'adhésion aux traitements antihypertenseur, car leur impact sur la vie quotidienne des patients peut s'avérer significatif.

Résumé L’arsenal des traitements de fond destinés aux patients atteints de sclérose en plaques a évolué ces dernières années. Lors de la délivrance, le pharmacien informe et conseille, optimise la gestion du traitement, détecte les effets indésirables et veille à l’observance. Lors d’un switch thérapeutique, le suivi doit être renforcé. Summary The therapeutic armamentarium for patients with multiple sclerosis has evolved over recent years. When dispensing long-term treatments, pharmacists must inform and advise, optimise the management of the treatment, detect adverse effects and ensure compliance. When a treatment is changed, the monitoring must be stepped up. [ABSTRACT FROM AUTHOR]

Copyright of Pan African Medical Journal is the property of Pan African Medical Journal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Résumé Introduction Quelques cas de surdité sous-hydroxychloroquine ont été décrits dans la littérature, la responsabilité de l’hydroxychloroquine restant cependant difficile à établir. Observation Nous rapportons le premier cas, à notre connaissance, de réintroduction positive de l’hydroxychloroquine à l’origine d’une surdité, chez une femme traitée pour un lupus systémique. Une revue des cas de surdité sous-hydroxychloroquine enregistrés dans la base nationale de pharmacovigilance permet de recenser au 31 décembre 2015, 23 observations de surdité lors de traitement par hydroxychloroquine dont 8 fois chez des patients lupiques. Conclusion Malgré son excellente tolérance et un rapport efficacité–effet indésirable important dans le lupus, cette observation apporte des arguments en faveur d’une ototoxicité possible de l’hydroxychloroquine. Introduction Several cases of hearing loss induced by hydroxychloroquine have been reported in the literature but the role of hydroxychloroquine still remains debated. Case report We report the first case, to our knowledge, of hearing loss induced by hydroxychloroquine with a positive re challenge in a woman treated for systemic lupus. An analysis of the French pharmacovigilance database allowed to identify 23 additional cases of hearing loss in patients treated with hydroxychloroquine and, among them, 8 had systemic lupus. Conclusion Despite an excellent tolerance and high efficacy–side effect ratio, this case report adds some evidence for an otoxicity of hydroxychloroquine. [ABSTRACT FROM AUTHOR]

Mild abnormal liver function is detected in 0.5%-3% of patients treated with antidepressants, and the incidence of drug-induced liver injury related to antidepressants is of 1.28-4 cases per 100,000 patient-years. Antidepressant liver toxicity is underestimated due to case under-declaration and absence of precise diagnostic criteria. The risk factors for antidepressant-induced liver injury are poorly known. Drug-drug interactions or a cross-toxicity for tricyclic antidepressants due to their similar tricyclic structure, have been described. A dose-response relationship was reported for duloxetine, nefazodone and mianserin. Liver toxicity due duloxetine seems to be more frequent in patients with underlying chronic liver disease. Temporal relationship between drug prescription and hepatotoxicity, as well as evolution of liver function tests upon drug discontinuation is essential diagnostic criteria. Liver damage is often of the hepatocellular type and less frequently of the cholestatic and mixed types. Generally, liver function tests rapidly normalize with drug withdrawal, but cases of fulminant hepatic failure have been described. The drugs for which the frequency of reported hepatic toxicity appears to be highest are monoamineoxidase inhibitors, tricyclic antidepressants, nefazodone, bupropion, duloxetine and agomelatine. Citalopram, escitalopram, paroxetine and fluvoxamine seem to have lower hepatotoxicity. Prompt discontinuation of the drug responsible and surveillance of liver function tests are essential. [ABSTRACT FROM AUTHOR]

Bullous pemphigoid affects people who are usually very frail, because they are very old and frequently have neurological co-morbidities. Over the past twenty years, therapeutic management has improved thanks to the application of highly potent corticosteroid-based creams, following a well-established regimen, for several months. Well-conducted nursing care is therefore essential not only to cover wounds, but also to treat the disease. Dedicated nursing time is also an opportunity to provide support to patients, who are often very uncomfortable., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)

The pandemic subsequent to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus resulted, for the French institutional pharmacovigilance, in a "health crisis" in 2 phases: the coronavirus disease 2019 - "COVID-19" phase during which the missions of the Regional Pharmacovigilance Centres (RPVC) were to detect a possible impact of drugs on this disease, as whether existed a possible aggravating role of certain drugs, or the safety profile of drugs used for the management of COVID-19 could evolve. The second phase followed the availability of COVID-19 vaccines, during which the RPVCs' missions were to detect as early as possible any new serious adverse effect, source of a potential signal that would modify the benefit/risk ratio of a vaccine and require the implementation of health safety measures. During these two periods, signal detection remained the core business of the RPVCs. The RPVCs had to organize themselves to handle an historical surge of declarations and requests for advice, whereas the RPVCs in charge of monitoring vaccines had to deal with an extraordinary dense activity over a long period of time, in order to produce in real time and on a weekly basis, a summary of all the declarations and an analysis of safety signals. The national organization put in place made it possible to meet the challenge of real-time pharmacovigilance monitoring of 4 vaccines with conditional marketing authorizations. Short-circuit efficient exchanges with the French Regional Pharmacovigilance Centres Network was paramount for the French National Agency for medicines and health products (Agence nationale de sécurité du médicament et des produits de santé) to develop an optimal collaborative partnership. The RPVC network has shown agility and flexibility, has been able to adapt swiftly and demonstrated its effectiveness in the early detection of safety signals. This crisis confirmed the superiority of manual/human signal detection as the most effective and powerful tool to date, to rapidly detect a new adverse drug reaction and enable to elaborate rapid measures of risk reduction. In order to maintain the performance of French RPVCs in signal detection and to monitor all drugs as they should and as expected by our fellow citizens, a new funding model correcting the inadequacy of RPVCs' expertise resources in relation to the volume of reports should be considered., (Copyright © 2023 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)

L'amiodarone est un médicament fréquemment prescrit pour lutter contre des troubles de la conduction cardiaque, au niveau auriculaire et ventriculaire. Son utilisation expose les patients à de nombreux effets indésirables, notamment à des dysthyroïdies pouvant majorer une maladie cardiovasculaire sous-jacente. Lors des dispensations, le pharmacien doit en tenir compte afin de détecter l'apparition de signes évocateurs et d'assurer un suivi clinique efficace de son patient. Amiodarone is a medicine frequently prescribed to treat impaired cardiac conduction, both atrial and ventricular. Its use exposes patients to numerous adverse effects, notably thyroid disorders which can aggravate underlying cardiovascular disease. When dispensing the medication, the pharmacist must take this into account in order to identify any signs suggestive of such disorders and to ensure the effective clinical follow-up of the patient. [ABSTRACT FROM AUTHOR]

Les fluoroquinolones présentent un spectre antibactérien élargi, des activités antibactériennes puissantes et des propriétés pharmacocinétiques améliorées avec une très bonne diffusion tissulaire permettant de traiter des infections systémiques. Mais lors de leur utilisation, des effets indésirables peuvent survenir. Il convient de bien les connaître pour une optimisation et une sécurité du traitement. Fluroquinolones are broad-spectrum antibiotics with strong antibacterial activities and optimal pharmacokinetic properties, with very good tissue penetration making them suitable for treating systemic infections. Many adverse effects are associated with their use. It is important to be aware of them in order to optimise the treatment and guarantee maximum safety. [ABSTRACT FROM AUTHOR]